Overview
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
Status:
Terminated
Terminated
Trial end date:
2008-12-01
2008-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Relypsa, Inc.
Criteria
Inclusion Criteria:- Participants on hemodialysis between the ages of 18 and 70 years, with serum potassium
levels of at least 5.5 mmol/L
- Adequately dialyzed (Kt/V ≥ 1.2)
Exclusion Criteria:
- History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders
or major gastrointestinal surgery.
- Severe constipation or irregular bowel habits.
- Unable to consume or tolerate the study-specific diet.